All In Biotech

Drug Trial Radar · NCT06769425

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 Combination Treatment in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

157

Planned (sponsor's estimate)

Start

May 7, 2025

Primary completion

May 7, 2026

Study completion Aug 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.

Conditions

  • Recurrent Ovarian Cancer
  • HER2-negative
  • Advanced Breast Cancer
  • TNBC
  • Advanced Prostate Cancer
  • Advanced Gastric Cancer

Interventions

  • HS-10502 + NHADrug

    HS-10502 + NHA

  • HS-10502 + HS-20093Drug

    HS-10502 + HS-20093

  • HS-10502+ ApatinibDrug

    HS-10502+ Apatinib

  • HS-10502 + HS-20089Drug

    HS-10502 + HS-20089

  • HS-10502 + Platinum + BevacizumabDrug

    HS-10502 + Platinum + Bevacizumab

  • HS-10502 + nab-paclitaxel or Docetaxel or IrinotecanDrug

    HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan

  • HS-10502 + BevacizumabDrug

    HS-10502 + Bevacizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) of HS-10502(Stage 1:Dose escalating stage)Time frame: Cycle 1 (21 days)
  2. Maximum applicable dose (MAD) of HS-10502(Stage 1:Dose escalating stage)Time frame: Cycle 1 (21days)
  3. Efficacy of HS-10502: Objective response rate (ORR)(Stage 2: Dose expansion stage)Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.